These topics were tagged with "Treatment"
-
16/05/2013 - Engagement with health care leads to more prompt HIV diagnosis and higher rates of virological suppression among gay men
Implications for 'test and treat' Pre-existing connection with primary health care is associated with more prompt diagnosis of HIV infection and an increased likelihood of viro... -
16/05/2013 - Predictors of response to second-line therapy — do the NRTIs matter?
A retrospective analysis suggests that treatment failure on a second-line regimen is as common with one or more new nucleoside reverse-transcriptase inhibitors as with none. The optimal manage... -
16/05/2013 - Lopinavir levels at delivery remain high enough in Swiss comparison
Lopinavir concentrations remained high enough to prevent mother-to-child transmission of HIV, without dose adjustment, in a comparison of pregnant and nonpregnant women taking lopinavir. But the Sw... -
16/05/2013 - EFV regimens maintained longer than NVP or LPV/r regimens in Spain
First-line antiretroviral regimens combining tenofovir/emtricitabine (TDF/FTC) with efavirenz (EFV) resulted in significantly less regimen switching than first-line regimens combining TDF/FTC with ... -
13/05/2013 - People more likely to keep HIV clinic appointments if they believe their care providers know them as a person
People who believe their care providers know them as a person are more likely to keep their HIV clinic appointments, research conducted in the United States and published in the online edi... -
13/05/2013 - Longer life span in South Africans starting ART with over 200 CD4s
Life expectancy in South Africans starting antiretroviral therapy (ART) with a CD4 count above 200 cells/µL is 70% to 86% of that in HIV-negative adults of the same age and sex and much longe... -
10/05/2013 - US: Updated opportunistic infection guidelines add info on IRIS, hepatitis, drug interactions
On May 7 the National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of America announced the release of revised G... -
10/05/2013 - Efavirenz more effective than nevirapine for children with HIV
HIV positive African children and adolescents treated with efavirenz (Sustiva) were less likely to experience virological failure than those using nevirapine (Viramune), according to a large compar... -
08/05/2013 - UD-led team develops mathematical model to measure hidden HIV
May 7, 2013--Scientists have long believed that measuring the amount of HIV in a person’s blood is an indicator of whether the virus is actively reproducing. A University of Delawar... -
06/05/2013 - Maternal abacavir, smoking tied to heart markers in HIV-exposed kids
HIV-exposed but uninfected (HEU) children of HIV-positive mothers who took abacavir, smoked, or drank alcohol had elevated levels of cardiac biomarkers that could signal heart trouble, according to... -
04/05/2013 - Bristol-Myers Squibb receives US FDA sNDA approval for use of SUSTIVA® (efavirenz) in HIV-1 infected pediatric patients
Approval offers a once-daily option as part of a regimen for HIV-1 infected infants as young as three months and weighing at least 3.5 kg “Capsule ... -
04/05/2013 - Staying with first ART regimen longer cuts CD4 failure risk in USA
Staying on a first-line antiretroviral therapy (ART) regimen longer—called persistency—significantly lowered chances of CD4 failure in a study at the University of Alabama at Birmingham... -
02/05/2013 - Ascletis gains China market rights from Janssen to a clinical stage HIV protease inhibitor
TMC310911 is third product in growing Ascletis pipeline of infectious disease and cancer therapeutics Hangzhou, China and Research Triangle Park, NC (April 30, 2013) – Ascletis today ann... -
02/05/2013 - Two one-pill regimens face off
The integrase-based option performed as well as the old efavirenz-based standby. Now that three single-tablet regimens are available for HIV treatment, competition for the "best" opt... -
29/04/2013 - Gilead receives Complete Response Letters from U.S. Food and Drug Administration for elvitegravir and cobicistat
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has received Complete Response Letters from the U.S. Food and Drug Admini... -
25/04/2013 - FDA: Prezista (darunavir) labeling changes
On April 24, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to update labeling with 48 week data from study TMC114-C228 for HIV-1 treatment experienced pe... -
25/04/2013 - Tenofovir exposure moderately higher with vs without cobicistat in healthy volunteers
Tenofovir maximum concentration and area under the concentration-time curve (AUC) were moderately higher when tenofovir disoproxil fumarate (TDF) was administered with the boosting agent cobicistat... -
23/04/2013 - Anti-HIV therapy appears to protect children's hearts, NIH network study shows
For children who have had HIV-1 infection since birth, the combination drug therapies now used to treat HIV appear to protect against the heart damage seen before combination therapies were availab... -
23/04/2013 - Poor CD4 gains with viral control tied to higher non-AIDS mortality
Poor CD4-cell gains in people who attain viral suppression with antiretroviral therapy (ART) were linked to higher non-AIDS mortality, according to results of a study in Denmark. Parents of HIV-pos... -
22/04/2013 - London HIV drug prescribing changes – patient satisfaction and clinical outcomes maintained
Controversial changes to the range of anti-HIV drugs which are most commonly prescribed in London have resulted in a £7.2 million saving over two years, with no sign of reduced patie... -
18/04/2013 - FDA: Changes to label for Atripla tablets
FDA recently approved changes to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that s... -
18/04/2013 - Antiretroviral therapy does not affect resting energy expenditure in HIV-infected women
Studies have shown that about 10 percent of men infected with human immunodeficiency virus (HIV) have an elevated resting energy expenditure (REE). Their bodies use more kilocalories for basic func... -
15/04/2013 - Life expectancy for South African patients who start HIV therapy with CD4 cell counts above 200 is 'near normal'
HIV-positive patients in South Africa can have a near-normal life expectancy, provided that they start antiretroviral therapy promptly, investigators report in the open access journal PLoS... -
15/04/2013 - Rilpivirine vs EFV 48-week response in naive with sub-100,000 load
Among people starting antiretroviral therapy (ART) with a viral load below 100,000 copies/mL, a higher proportion randomized to rilpivirine than to efavirenz (EFV) had a 48-week load below 50 copie... -
15/04/2013 - Some subtype differences in NNRTI resistance with ETV versus RPV
HIV-1 harboring different key nonnucleoside (NNRTI) resistance mutations sometimes evolved to generate different additional resistance mutations when exposed to rilpivirine (RPV) or etravirine (ETV... -
14/04/2013 - Treatment Action Group: tagline Spring 2013
News on the fight to end HIV/AIDS, viral hepatitis, and tuberculosis The newsletter is available here: http://www.treatmentactiongroup.org/tagline/2013/spring. ... -
13/04/2013 - Early CD4 gains in gut with ART, plus decreased immune activation
CD4 cells repopulated the large and small intestine when people with chronic HIV infection started antiretroviral therapy (ART), according to results of biopsy studies. Although CD4-cell levels did... -
09/04/2013 - Aging does not affect CD4 change in Australians on suppressive cART
Aging and duration of combination antiretroviral therapy (cART) did not affect CD4-cell changes in an Australian cohort taking long-term effective cART. Natural aging may promote a long-term d... -
05/04/2013 - Combo defeats fungal meningitis in HIV
Induction therapy with combined amphotericin B and flucytosine improved survival in HIV-positive patients with cryptococcal meningitis, a randomized trial determined. The hazard ratio for death... -
03/04/2013 - HIV i-Base: HIV Treatment Bulletin: April 2013
Volume 14 Number 3/4 March/April 2013 The online version is available at http://i-base.info/htb/date/2013/04. ...
News
You can also search the entire site for "Treatment" by clicking here